FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3211763013> ?p ?o ?g. }

• W3211763013 abstract "Astragaloside IV (AS-IV) has been used to treat cardiovascular disease. However, whether AS-IV exerts a protective effect against hypertensive heart disease has not been investigated. This study aimed to investigate the antihypertensive and cardioprotective effects of AS-IV on L-NAME-induced hypertensive rats via network pharmacology and experimental pharmacology. The network pharmacology and bioinformatics analyses were performed to obtain the potential targets of AS-IV and hypertensive heart disease. The rat hypertension model was established by administrated 50 mg/kg/day of L-NAME for 5 weeks. Meanwhile, hypertension rats were intragastrically administrated with vehicle or AS-IV or fosinopril for 5 weeks. Cardiovascular parameters (systolic blood pressure, diastolic blood pressure, mean arterial pressure, heart rates, and body weight), cardiac function parameters (LVEDd, LVEDs, and fractional shortening), cardiac marker enzymes (creatine kinase, CK-MB, and lactate dehydrogenase), cardiac hypertrophy markers (atrial natriuretic peptide and brain natriuretic peptide), endothelial function biomarkers (nitric oxide and eNOS), inflammation biomarkers (IL-6 and TNF-α) and oxidative stress biomarkers (SOD, MDA, and GSH) were measured and cardiac tissue histology performed. Network pharmacological analysis screened the top 20 key genes in the treatment of hypertensive heart disease treated with AS-IV. Besides, AS-IV exerted a beneficial effect on cardiovascular and cardiac function parameters. Moreover, AS-IV alleviated cardiac hypertrophy via down-regulating the expression of ANP and BNP and improved histopathology changes of cardiac tissue. AS-IV improved endothelial function via the up-regulation of eNOS expression, alleviated oxidative stress via increasing antioxidant enzymes activities, and inhibited cardiac inflammation via down-regulating IL-6 and TNF-α expression. Our findings suggested that AS-IV is a potential therapeutic drug to improve L-NAME-induced hypertensive heart disease partly mediated via modulation of eNOS and oxidative stress." @default.
• W3211763013 created "2021-11-22" @default.
• W3211763013 creator A5002093140 @default.
• W3211763013 creator A5024563485 @default.
• W3211763013 creator A5029829921 @default.
• W3211763013 creator A5030725969 @default.
• W3211763013 creator A5054758529 @default.
• W3211763013 creator A5062245370 @default.
• W3211763013 creator A5065592637 @default.
• W3211763013 creator A5073164618 @default.
• W3211763013 creator A5077749222 @default.
• W3211763013 date "2021-11-05" @default.
• W3211763013 modified "2023-10-17" @default.
• W3211763013 title "The Mechanism Actions of Astragaloside IV Prevents the Progression of Hypertensive Heart Disease Based on Network Pharmacology and Experimental Pharmacology" @default.
• W3211763013 cites W1552241499 @default.
• W3211763013 cites W1560721086 @default.
• W3211763013 cites W1685675634 @default.
• W3211763013 cites W1972465295 @default.
• W3211763013 cites W1992952078 @default.
• W3211763013 cites W1996530980 @default.
• W3211763013 cites W2016209708 @default.
• W3211763013 cites W2019698882 @default.
• W3211763013 cites W2037200837 @default.
• W3211763013 cites W2057623019 @default.
• W3211763013 cites W2068517891 @default.
• W3211763013 cites W2074894281 @default.
• W3211763013 cites W2081079039 @default.
• W3211763013 cites W2081948412 @default.
• W3211763013 cites W2089290778 @default.
• W3211763013 cites W2094176510 @default.
• W3211763013 cites W2095140180 @default.
• W3211763013 cites W2098185039 @default.
• W3211763013 cites W2101300574 @default.
• W3211763013 cites W2103686416 @default.
• W3211763013 cites W2106425800 @default.
• W3211763013 cites W2114104950 @default.
• W3211763013 cites W2124284996 @default.
• W3211763013 cites W2149098310 @default.
• W3211763013 cites W2153195779 @default.
• W3211763013 cites W2155504581 @default.
• W3211763013 cites W2313349434 @default.
• W3211763013 cites W2402512709 @default.
• W3211763013 cites W2581157121 @default.
• W3211763013 cites W2807234584 @default.
• W3211763013 cites W2919463374 @default.
• W3211763013 cites W2945244872 @default.
• W3211763013 cites W2950389925 @default.
• W3211763013 cites W2951594013 @default.
• W3211763013 cites W2966794993 @default.
• W3211763013 cites W2970842411 @default.
• W3211763013 cites W2986964441 @default.
• W3211763013 cites W2995653856 @default.
• W3211763013 cites W3000533972 @default.
• W3211763013 cites W3008065272 @default.
• W3211763013 cites W3011719960 @default.
• W3211763013 cites W3093998613 @default.
• W3211763013 cites W3126426221 @default.
• W3211763013 cites W4242171500 @default.
• W3211763013 cites W647542028 @default.
• W3211763013 cites W978308701 @default.
• W3211763013 doi "https://doi.org/10.3389/fphar.2021.755653" @default.
• W3211763013 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8602690" @default.
• W3211763013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34803698" @default.
• W3211763013 hasPublicationYear "2021" @default.
• W3211763013 type Work @default.
• W3211763013 sameAs 3211763013 @default.
• W3211763013 citedByCount "5" @default.
• W3211763013 countsByYear W32117630132022 @default.
• W3211763013 countsByYear W32117630132023 @default.
• W3211763013 crossrefType "journal-article" @default.
• W3211763013 hasAuthorship W3211763013A5002093140 @default.
• W3211763013 hasAuthorship W3211763013A5024563485 @default.
• W3211763013 hasAuthorship W3211763013A5029829921 @default.
• W3211763013 hasAuthorship W3211763013A5030725969 @default.
• W3211763013 hasAuthorship W3211763013A5054758529 @default.
• W3211763013 hasAuthorship W3211763013A5062245370 @default.
• W3211763013 hasAuthorship W3211763013A5065592637 @default.
• W3211763013 hasAuthorship W3211763013A5073164618 @default.
• W3211763013 hasAuthorship W3211763013A5077749222 @default.
• W3211763013 hasBestOaLocation W32117630131 @default.
• W3211763013 hasConcept C111566952 @default.
• W3211763013 hasConcept C126322002 @default.
• W3211763013 hasConcept C134018914 @default.
• W3211763013 hasConcept C27016395 @default.
• W3211763013 hasConcept C2775846464 @default.
• W3211763013 hasConcept C2776151105 @default.
• W3211763013 hasConcept C2777622882 @default.
• W3211763013 hasConcept C2778069365 @default.
• W3211763013 hasConcept C2778198053 @default.
• W3211763013 hasConcept C2778326061 @default.
• W3211763013 hasConcept C2780045698 @default.
• W3211763013 hasConcept C2780074459 @default.
• W3211763013 hasConcept C2780436477 @default.
• W3211763013 hasConcept C519581460 @default.
• W3211763013 hasConcept C71924100 @default.
• W3211763013 hasConcept C84393581 @default.
• W3211763013 hasConcept C98274493 @default.
• W3211763013 hasConceptScore W3211763013C111566952 @default.
• W3211763013 hasConceptScore W3211763013C126322002 @default.
• W3211763013 hasConceptScore W3211763013C134018914 @default.

• next